We are pleased with the progress of our NGS initiative to create a complete portfolio of products and services to make this breakthrough technology more effective, robust and scalable for areas such as clinical research and diagnostics, said Peer M. Schatz, Chief Executive Officer of QIAGEN. The development of our complete sample-to-result workflow is a key achievement in our initiative to offer